Living with a spinal cord injury changes how you move, feel, and function every day. You might be searching for more support in your recovery or looking into alternatives when other treatments have plateaued. At Stemedix, we provide access to regenerative medicine options, including stem cell therapy for spinal cord injury, designed to support your body’s healing potential. Our goal is to help you maintain independence and improve your quality of life through individualized care.
Stem cells for the treatment of spinal cord injury are being explored for their ability to support damaged nerve tissues and help reduce symptoms related to mobility, pain, and function. This therapy is not a cure, but it may serve as another layer of support in your recovery process. In this article, we will discuss how spinal cord injuries affect the body and how stem cell treatment may fit into your path forward.
Defining Spinal Cord Injury: Causes and Impact
A spinal cord injury doesn’t just affect mobility—it changes how the entire body communicates, functions, and adapts. Knowing how these injuries happen and what they cause can help you better plan your care and treatment options.
Common Causes of Spinal Cord Injury
A spinal cord injury is most often caused by sudden trauma or underlying medical conditions that disrupt nerve communication within the spine. These injuries commonly follow events such as vehicle crashes, major falls, sports-related impacts, or violent encounters.
Other cases develop from non-traumatic sources. These include conditions like spinal tumors, multiple sclerosis, and certain infections that interfere with the spinal cord’s structure and function. Degenerative diseases—such as spinal stenosis or arthritis—can also contribute to gradual nerve damage over time.
A spinal cord injury disrupts messages between the brain and the rest of the body. Where the injury occurs determines what parts of the body are affected. For example, if damage happens in the cervical spine, it can interfere with both arm and leg function. A lower injury in the lumbar region, by contrast, may impact only the hips and legs.
Immediate and Long-Term Effects on the Body
A spinal cord injury can result in paralysis, loss of sensation, and autonomic system dysfunction. Right after the injury, you might notice loss of movement, reduced feeling in certain areas, or changes in bladder and bowel control. These effects often appear quickly and may be temporary or permanent, depending on the severity.
As time passes, new challenges can appear. You may notice muscle weakness from disuse, skin breakdown from reduced movement, or respiratory changes if the injury is high enough to affect breathing muscles. Pressure injuries, also called pressure sores, and recurrent infections such as urinary tract infections are common secondary complications that require careful management. These long-term impacts highlight the importance of continuous support and well-structured care plans.
Classification of Spinal Cord Injuries by Severity and Location
Knowing where and how a spinal cord injury occurs helps you and your care team decide on the right approach to managing your recovery. The level and type of injury directly impact physical abilities, personal care needs, and long-term health planning.
Complete vs. Partial Injury Overview
A complete spinal cord injury causes total loss of motor and sensory function, while a partial injury retains some level of nerve signal transmission. If you’ve been diagnosed with a complete spinal cord injury, it means there’s no communication between the brain and the body below the injury site. This disconnect leads to full paralysis and loss of sensation below that point.
In contrast, partial, also called incomplete injuries, allow some signals to continue traveling along the spinal cord. You may notice that you still have some sensation, or you may be able to move certain muscles. These residual functions vary greatly between individuals. This classification matters because it plays a role in setting realistic goals for therapy and rehabilitation.
Differences Between Cervical, Thoracic, and Lumbar Injuries
The location of a spinal cord injury determines which parts of the body are affected. Cervical injuries often result in quadriplegia, thoracic injuries affect trunk and leg function, and lumbar injuries primarily impair lower limb control and bowel or bladder management.
Cervical injuries, those in the neck region, are often the most severe. They can impact movement and feeling in all four limbs, including breathing, swallowing, and arm function. These types are the most likely to require long-term assistive devices or full-time care.
Thoracic injuries occur in the middle section of the spine. While they typically spare arm movement, they may limit balance, torso strength, and control over abdominal muscles. It may be harder to sit upright or regulate body temperature below the injury level.
Lumbar injuries involve the lower spine and tend to affect the legs and lower body systems. Many people with lumbar-level injuries retain upper body function, but mobility challenges and changes in bladder or bowel function often follow. This type of injury may still allow for independent movement with the use of braces, walkers, or wheelchairs.
At Stemedix, we review all available medical records to understand your specific injury type and level before recommending any regenerative treatment option. This allows us to align our approach with your needs and current capabilities.
Stem Cell Therapy Explained: Purpose and Methods
Stem cell therapy for spinal cord injury involves introducing regenerative cells to promote repair and protect surviving tissue. These cells are introduced into areas near the injury site, where they may influence several healing processes. One of the primary actions is the regulation of the immune response, which helps reduce further damage caused by ongoing inflammation. In addition, stem cells may release biological signals that support the health of existing nerve cells and encourage the development of new connections within the nervous system.
Types of Stem Cells Used in Therapy
Stem cells for the treatment of spinal cord injury may sometimes include mesenchymal stem cells (MSCs), neural stem cells, and induced pluripotent stem cells (iPSCs). Each type works differently, but MSCs are the most frequently used in current therapeutic models. These cells are typically harvested from bone marrow or adipose (fat) tissue. They’re known for their ability to regulate inflammation and release molecules that promote healing.
Neural stem cells, on the other hand, are more specialized and are under investigation for their ability to integrate into damaged neural circuits. Induced pluripotent stem cells, adult cells reprogrammed into a more flexible, embryonic-like state, are still largely in the research phase. Although they offer broader potential, their use requires rigorous safety protocols to manage risks like tumor formation.
At Stemedix, we focus on therapies that use stem cells for the treatment of spinal cord injury with strong safety records and established handling procedures. Our team works closely with patients and referring physicians to coordinate care that is both informed by current science and centered on individual medical history.
Biological Actions of Stem Cells in Nerve Repair
Stem cells offer more than just cellular replacement—they create conditions in the body that support repair and healing. When applied to spinal cord injury, their effects can influence both immune activity and tissue regeneration.
Influence on Inflammation and Immune Response
Stem cells help regulate immune responses and reduce secondary damage from inflammation. After a spinal cord injury, inflammation can lead to further damage beyond the initial trauma. Immune cells flood the site, often destroying nearby healthy tissue in the process. This secondary damage can be just as limiting as the original injury.
Stem cells interact with this process by releasing bioactive molecules like cytokines and growth factors. These signals tell immune cells to calm their response and shift toward tissue support instead of attack.
This immune-modulating activity helps preserve nerve cells that might otherwise deteriorate. You’re not just adding cells—you’re also working with your body’s existing systems to limit further harm and stabilize the injury site.
Role in Regenerating Damaged Neural Tissue
Stem cell treatment for spinal cord injury may support the formation of new neural connections and repair mechanisms. Spinal cord damage disrupts the flow of signals between your brain and body.
To support repair, stem cells may promote three biological processes: axonal growth, remyelination, and cellular restoration. Axonal growth refers to the extension of nerve fibers that transmit signals. Without axons, communication between nerves stops.
Remyelination involves restoring the protective sheath around nerves, which allows electrical impulses to travel efficiently. In cases of spinal cord injury, this sheath often breaks down, leading to slower or blocked signals.
Studies show that certain types of stem cells, including induced pluripotent stem cells (iPSCs) and MSCs, can release growth factors that encourage axons to regrow and remyelinate existing nerves. These biological effects don’t occur all at once. They build over time as the cells interact with damaged tissue, guiding regeneration step by step.
At Stemedix, we focus on regenerative strategies that support your body’s efforts to recover. Stem cell therapy for spinal cord injury is structured to work with your body, using natural signaling processes to support healing at the cellular level.
Observed Outcomes from Stem Cell Treatments
Many individuals exploring regenerative options want to know what to expect from stem cell therapy. While results can differ, this section outlines some of the most reported effects based on real patient experiences and clinical data.
Enhancements in Mobility and Sensory Recovery
Some patients receiving stem cell treatment for spinal cord injury report improved strength, coordination, and sensation. These outcomes are often influenced by the level and completeness of the injury. For example, individuals with incomplete spinal cord injuries—where the spinal cord is damaged but not fully severed—have demonstrated positive changes in limb control, trunk stability, and tactile feedback following therapy.
Certain patients experienced measurable improvements in motor scores and sensory function within months after receiving stem cell injections. These functional changes, although not universal, suggest that the cells may support the body’s effort to reconnect or reinforce neural pathways.
The timing of intervention also plays a role. People who began stem cell treatment in the sub-acute phase (weeks after injury) have shown different patterns of recovery compared to those in chronic stages. It’s important to consider that early intervention may help maximize the biological environment for healing, but research is still ongoing to determine the full scope of response across timelines.
Reduction of Discomfort and Muscle-Related Symptoms
Stem cells have been observed to reduce spasticity and neuropathic pain associated with spinal cord injury. Spasticity, which causes involuntary muscle contractions, and nerve-related pain are among the most persistent challenges following spinal trauma. These symptoms can disrupt sleep, limit mobility, and interfere with rehabilitation.
Some patients who received mesenchymal stem cell (MSC) therapy reported decreased muscle stiffness and better pain control. Stem cell infusions modulated the immune response and contributed to reduced inflammation around damaged spinal segments. This shift may help explain why pain and tightness sometimes improve after treatment.
Relief from these symptoms can create opportunities for more active daily routines and improved engagement in physical therapy. While stem cell therapy is not a replacement for traditional pain management or rehabilitation, it may complement those approaches in supportive ways.
At Stemedix, we’ve seen that outcomes vary depending on the person’s overall health, injury characteristics, and treatment timing. Our role is to offer access to care designed around your condition while helping you understand how regenerative therapy might fit into your goals for living with a spinal cord injury.
The Treatment Process at Stemedix: Patient-Centered Approach
Every individual with a spinal cord injury presents a unique medical profile. At Stemedix, based in Saint Petersburg, FL, we align the treatment process with your personal health history and therapy goals to support your experience from evaluation through follow-up.
Importance of Diagnostic Information From Referring Physicians
Stemedix requires patients to provide medical imaging and records from their diagnosing physicians to determine eligibility for stem cell therapy. We rely on your existing records—such as MRIs, CT scans, and clinical summaries—to fully understand the scope of your spinal cord injury. This information gives us a starting point to evaluate whether stem cell therapy may be appropriate for your situation.
A detailed medical history helps our team determine the location and severity of your injury while also providing insight into how your body has responded to previous interventions. Accurate documentation from your physician allows us to move forward responsibly and reduce avoidable risks during the treatment process.
Tailoring Treatments to Individual Medical Histories
Each stem cell treatment for spinal cord injury is customized according to the patient’s health condition, injury level, and treatment goals. We look at a range of personal factors before planning treatment. These include the type of spinal cord injury you’ve experienced—whether complete or incomplete—as well as how long it has been since the initial trauma. Conditions like diabetes, autoimmune disorders, or chronic infections, as well as the medications you’re currently using, are all taken into account.
Administration Protocols and Safety Measures
Stemedix uses sterile, clinically guided protocols for administering stem cells. Each procedure is conducted in a controlled medical setting under the direction of trained clinicians. We use laboratory-tested biologics and sterile techniques to lower the risk of complications. All patients are closely observed before, during, and after the procedure.
Throughout treatment, we document patient responses, both for clinical records and to support communication with your existing care team. This consistent monitoring helps track progress and contributes to adjusting your care as needed over time. According to clinical studies, stem cell therapy has been associated with neurological improvements in some individuals with chronic spinal cord injuries, especially when introduced within a defined therapeutic window.
Patient Support Beyond Therapy
Recovery involves more than medical treatment alone. At Stemedix, we understand the physical and logistical challenges you may face when dealing with a spinal cord injury. That’s why we help coordinate accessible transportation and lodging for patients traveling from out of town, easing the burden of planning and focusing attention on your care.
To support your comfort during therapy, we provide access to mobility aids like wheelchairs and walkers, along with personal assistance when needed. Our team creates an accessible environment that allows you to move through treatment with as much comfort and independence as possible.
Start Your Recovery Journey with Stemedix Today
If you’re exploring advanced treatment options for spinal cord injury, our team at Stemedix is here to guide you every step of the way. We offer patient-focused care, treatment coordination, and support services designed around your individual needs. To learn more or speak with a care coordinator, call us at(727) 456-8968 or email yourjourney@stemedix.com.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can damage many different parts of the body, including the kidneys, lungs, brain, and blood system. Because it can attack so many organs, it often leads to serious illness and even death.
For many years, doctors have used medications like corticosteroids, cyclophosphamide (CTX), and mycophenolate mofetil (MMF) to control the disease. These treatments have helped patients live longer and have reduced the chances of severe organ failure. However, even with these medications, controlling SLE can still be very difficult for some patients.
Researchers have also developed newer drugs that target specific parts of the immune system, such as rituximab, belimumab, and tocilizumab, among others. While these drugs have improved outcomes for many people, they can sometimes cause serious side effects or lead to the disease coming back once the medication is stopped. Because of these challenges, scientists have been searching for new ways to treat SLE, and one promising option is stem cell therapy.
As part of this review, Yuan et al. explore how stem cells are being used to treat lupus, including the different types of stem cells, the challenges involved, and what the future of treatment may hold.
Hematopoietic Stem Cells and Their Role in Lupus Treatment
Hematopoietic stem cells (HSCs) are the type of stem cells that create all other blood cells. First discovered in 1961, HSCs have become important in treating both blood cancers and autoimmune diseases. In 1997, doctors began using HSC transplants (HSCT) to treat patients with both blood cancers and autoimmune diseases. The results demonstrated that not only did the cancers improve, but the autoimmune symptoms also got better.
Since then, many studies around the world have tested HSCT in people with SLE, and the results have been very encouraging – with patients even showing signs of what researchers call a “fundamental cure,” meaning their disease improved dramatically over the long term.
How Lupus Affects Stem Cells
SLE itself can harm the body’s natural stem cells. Research has shown that people with lupus have lower levels of circulating HSCs and endothelial progenitor cells (which help repair blood vessels). This loss of stem cells may be caused by an increase in programmed cell death, known as apoptosis. As a result, lupus patients may have a harder time repairing blood vessels, leading to problems like atherosclerosis (hardening of the arteries).
Other studies have found that certain changes in the immune system can make stem cells more likely to die off. For example, increased activity in a pathway called mTOR has been linked to poor blood cell production in mice with autoimmune diseases. However, research has also shown the opposite, with lupus conditions causing an increase in stem cells that behave abnormally.
Because of these differences, the authors indicate the need for further research to fully understand how lupus affects stem cells.
Comparing Hematopoietic and Mesenchymal Stem Cells
Because of the challenges with hematopoietic stem cells, researchers have also explored using mesenchymal stem cells (MSCs). MSCs come from bone marrow, fat tissue, or umbilical cord blood, and they have powerful anti-inflammatory and immune-regulating effects.
Clinical studies have shown that about 60% of patients responded well to the treatment, and there were very few serious side effects. This finding opened the door to a whole new field of lupus treatment research.
One significant difference between HSCT and MSC therapy is that MSCs do not require the intense and risky immune system wipe-out that HSCT does. Instead, MSCs can be infused into the body and work to rebalance the immune system naturally. Because of this, MSC therapy is generally safer, has fewer complications, and is more affordable than HSCT.
Another reason MSCs are so promising is that bone marrow MSCs from lupus patients often show structural and functional abnormalities, which means that transplanting healthy MSCs from a donor could help correct some of the immune system issues at the root of the disease.
Animal studies have strongly supported the effectiveness of MSCs in treating lupus, and early clinical trials in humans have shown encouraging results. Phase I and II studies suggest that MSC therapy is both safe and effective for SLE patients, but further larger clinical trials are needed to confirm these findings and to better understand exactly how MSCs help heal the immune system.
The Future of Stem Cell Therapy for Lupus
Stem cell therapy offers exciting new possibilities for patients with SLE who have not had success with traditional treatments. Hematopoietic stem cell transplants have been shown to help many patients, sometimes even achieving long-term remission. However, because of the high risks and costs involved, HSCT is likely to remain a treatment reserved for the most severe and treatment-resistant cases.
Mesenchymal stem cell therapy, on the other hand, appears to offer a safer, more accessible option that could benefit a much larger number of patients. With fewer side effects, lower relapse rates, and easier treatment protocols, MSCs are quickly becoming a major focus of research into better lupus treatments.
At the same time, the authors continue to study exactly how stem cells work to regulate the immune system. They are also working on ways to improve the safety and effectiveness of both HSCT and MSC treatments. According to Yuan et al, goals for the future include finding better ways to prevent infections, lowering relapse rates, and understanding the long-term effects of stem cell therapy. Researchers are also exploring how to personalize stem cell therapies based on each patient’s unique immune system and genetic background, which could lead to even better outcomes.
Yuan et al. conclude that while traditional lupus treatments have made great strides over the past few decades, there is still a significant need for new and better therapies, especially for patients whose disease does not respond to standard medications.
Stem cell therapy, particularly with mesenchymal stem cells, represents a promising new frontier in the fight against lupus. Ongoing research and clinical trials will help clarify how best to use stem cells to treat SLE safely and effectively, offering new hope for people living with this challenging disease.
Source: Yuan X, Sun L. Stem Cell Therapy in Lupus. Rheumatol Immunol Res. 2022 Jul 6;3(2):61-68. doi: 10.2478/rir-2022-0011. PMID: 36465325; PMCID: PMC9524813.
Knee osteoarthritis (OA) is a long-term condition that affects millions of people worldwide. It occurs when the cartilage in the knee begins to break down, often due to aging, injury, or repeated stress on the joint. Early signs of OA include swelling, stiffness, and pain in the knee. Over time, the condition worsens, leading to a narrowing of the space between bones, the development of bony growths (osteophytes), and reduced joint mobility. This progression can significantly impact a person’s quality of life, especially in older adults.
One of the major challenges in treating knee OA is the poor ability of cartilage to repair itself. Cartilage lacks blood vessels and relies on nearby joint fluid and surrounding tissues for nutrients, making it especially vulnerable to damage. As a result, finding effective ways to heal or regenerate damaged cartilage has been a major focus of research in recent years.
In this review, Zhang et al. summarize the basic research and clinical studies to promote inflammatory chondrogenesis in the treatment of OA and provide a theoretical basis for clinical treatment.
The Role of Stem Cells in Cartilage Repair
Researchers have explored several treatment options for OA, including injections of corticosteroids, platelet-rich plasma, sodium hyaluronate, and more recently, stem cells. Among the various stem cell types being studied, human umbilical cord mesenchymal stem cells (HUC-MSCs) have shown promising results.
HUC-MSCs are a type of stem cell collected from the umbilical cords of newborns. These cells are especially attractive for medical use because they are easy to obtain, do not cause pain or harm to the donor, and are free from the ethical concerns that sometimes surround embryonic stem cells. They have also demonstrated the ability to multiply, change into different cell types (including cartilage cells), and regulate inflammation in the body.
Biological Benefits of HUC-MSCs in OA Treatment
According to the authors, what sets HUC-MSCs apart is their ability to both repair cartilage and control the inflammatory processes that worsen OA. These cells release helpful substances like cytokines, growth factors, and extracellular vesicles that support cartilage repair and reduce joint inflammation. HUC-MSCs can also develop into chondrocytes – cells that produce and maintain healthy cartilage.
In studies comparing HUC-MSCs to bone marrow-derived stem cells, HUC-MSCs have shown a higher potential for cartilage formation and a lower tendency to become fat or bone cells. These qualities make them a strong candidate for regenerating joint cartilage in OA patients. Additionally, the extracellular matrix (ECM) they produce is rich in type II collagen, which is essential for building strong, healthy cartilage.
Another biological benefit of HUC-MSCs is their ability to function well in low-oxygen environments, such as the interior of a joint. This makes them well suited for surviving and thriving in the harsh conditions of damaged knee joints. They also produce anti-inflammatory proteins like IL-10 and TGF-β1, which help reduce pain and inflammation, making the joint environment more suitable for healing.
Clinical Use of HUC-MSCs and Evidence of Effectiveness
Over the past decade, HUC-MSCs have been tested in laboratory studies, animal models, and human clinical trials. Results consistently show that these cells can improve symptoms, protect joint structures, and possibly slow the progression of OA.
In animal models of OA, researchers found that injecting HUC-MSCs into the knee joint helped reduce cartilage breakdown and cell death. In these studies, both single and repeated injections produced similar benefits, including better cartilage matrix production and less joint degeneration.
In human trials, HUC-MSCs have been tested in patients with moderate to severe OA. Results show improved joint function, reduced pain, and even signs of new cartilage formation on imaging studies. When compared to traditional treatments like sodium hyaluronate injections, HUC-MSC therapy has been shown to offer faster, longer-lasting relief and more meaningful improvements in joint health.
Additionally, treatment with HUC-MSCs has proven to be well tolerated and safe, with no serious side effects reported. Minor discomfort after the injection was typically short-lived and did not require medical intervention.
Mechanisms of Action and How HUC-MSCs Promote Healing
Zhang et al. found that HUC-MSCs help reduce the harmful effects of OA in several ways. First, they lower levels of inflammatory molecules like IL-1β, TNF-α, and IL-6 that are commonly found in arthritic joints. These substances are responsible for breaking down cartilage and increasing pain. HUC-MSCs also block enzymes such as MMP-13 and ADAMTS-5, which are known to degrade the cartilage structure.
At the same time, HUC-MSCs boost the production of cartilage-supporting proteins like collagen type II, aggrecan, and SOX9. These proteins are critical for rebuilding and maintaining the smooth, elastic tissue that cushions the ends of bones in the joint.
In addition to their anti-inflammatory and regenerative properties, HUC-MSCs influence the immune system by shifting inflammatory cells from a damaging state to a healing state. This shift helps calm the immune response within the joint and supports the repair process.
Several key cell signaling pathways – such as PI3K/Akt, mTOR, and Notch – are involved in this regenerative process. These pathways help control cell survival, growth, and the formation of new cartilage. As researchers continue to uncover how these pathways work, the authors anticipate new possibilities for targeted therapies will emerge.
Advantages Over Traditional and Other Stem Cell Treatments
Compared to other types of stem cells, such as those taken from bone marrow or fat tissue, HUC-MSCs offer multiple advantages. They are more readily available, easier to collect, and carry less risk of causing an unwanted immune response. They also multiply faster, have a greater capacity to form cartilage, and are less likely to develop into bone or fat cells – features that are particularly important when the goal is to repair joint cartilage.
Unlike treatments that simply reduce symptoms, such as painkillers or steroid injections, HUC-MSC therapy has the potential to address the root cause of OA by rebuilding damaged cartilage and rebalancing the joint’s internal environment.
Because of these advantages, the authors believe HUC-MSCs may represent a major step forward in the treatment of OA, especially for patients who have not responded well to traditional therapies or who are looking for a regenerative option before considering surgery.
A Promising Path Forward for Osteoarthritis Care
Human umbilical cord mesenchymal stem cells offer a new and exciting option for patients with knee osteoarthritis. With their ability to reduce inflammation, promote cartilage repair, and restore joint function, HUC-MSCs are rapidly becoming an important focus in regenerative medicine. As more research is conducted and the science behind these cells becomes clearer, they may soon become a standard part of OA treatment, offering hope for millions of people living with joint pain and stiffness.
Zhang P, Dong B, Yuan P, Li X. Human umbilical cord mesenchymal stem cells promoting knee joint chondrogenesis for the treatment of knee osteoarthritis: a systematic review. J Orthop Surg Res. 2023 Aug 29;18(1):639. doi: 10.1186/s13018-023-04131-7. PMID: 37644595; PMCID: PMC10466768.
Neurodegenerative diseases like Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) are among the most challenging medical conditions to treat. These disorders involve the gradual breakdown and loss of neurons in specific areas of the nervous system, leading to symptoms such as memory loss, paralysis, and impaired movement or cognition.
Despite decades of research and billions of dollars in clinical trials, researchers have yet to find a cure for these conditions, and even effective treatments remain limited. As a result, neurodegenerative diseases place a significant emotional, physical, and economic burden on individuals, families, and healthcare systems worldwide.
In this review, Sivandzade et al. summarize the current knowledge of stem-cell-based therapies in neurodegenerative diseases and the recent advances in this field.
The Potential of Stem Cells in Treating Neurodegenerative Disorders
In recent years, regenerative medicine, particularly stem cell therapy, has emerged as an exciting new frontier in the treatment of neurodegenerative diseases. Stem cells have the remarkable ability to become various types of specialized cells in the body. In the context of neurodegenerative diseases, they may be able to repair damaged tissue, replace lost neurons, or create a healthier environment in the brain or spinal cord that helps preserve existing cells.
This unique potential has led researchers to explore whether stem cells could help slow disease progression, reduce symptoms, or even restore lost function in patients affected with these conditions.
Stem Cell Therapy Approaches in Neurological Disorders
Stem cell therapy strategies for neurodegenerative diseases typically fall into two main approaches. The first involves directly replacing the specific types of neurons that are lost during the disease process. For example, researchers aim to generate dopamine-producing neurons for patients with PD or restore damaged motor neurons in people with ALS. The second approach focuses on environmental enrichment, where stem cells are used to support the body’s own repair mechanisms. According to the authors, this could involve delivering neuroprotective growth factors like brain-derived neurotrophic factor (BDNF) or glial cell line-derived neurotrophic factor (GDNF), which help nourish and protect surviving neurons.
Recent research has also explored combining both strategies – using stem cells to replace lost cells while simultaneously enhancing the surrounding environment.
Stem Cell Therapy for Parkinson’s Disease
In Parkinson’s disease, the main issue is the gradual loss of dopamine-producing neurons in a part of the brain called the substantia nigra. This loss leads to symptoms like tremors, muscle rigidity, and slowed movement, usually appearing in people between their 50s and 70s.
Current treatments focus on increasing dopamine levels or using deep brain stimulation to control symptoms. While helpful, these options do not stop or reverse the underlying neuron loss. Stem cell therapy offers a promising alternative by aiming to replace the lost dopamine neurons or protect those that remain.
Recent studies have used embryonic stem cells (ESCs) to produce new dopamine-producing cells that can be transplanted into animal models of PD. These cells have shown the ability to migrate to damaged areas and improve motor function. However, ESCs come with ethical concerns and a risk of tumor formation, which has limited their use in human trials.
Mesenchymal stem cells (MSCs) have also shown potential in PD animal models by helping rebuild damaged dopamine nerve networks. Additionally, induced pluripotent stem cells (iPSCs) – adult cells reprogrammed to act like embryonic stem cells – have recently gained attention because they can be used to generate personalized dopamine-producing neurons without the ethical concerns associated with ESCs. These iPSC-derived neurons have shown promising results in animal models, surviving and integrating into the brain while improving motor symptoms.
Stem Cell Therapy for Alzheimer’s Disease
For patients with Alzheimer’s disease, the situation is more complex. AD is the most common neurodegenerative disease, affecting over 5 million Americans. It leads to memory loss, confusion, impaired judgment, and eventually complete cognitive decline. The disease is marked by the buildup of two harmful proteins in the brain: amyloid-beta, which forms plaques outside neurons, and tau, which forms complex tangles inside them. These protein abnormalities disrupt communication between brain cells and eventually cause them to die. Current medications focus on improving symptoms and slowing progression, but they do not reverse the damage.
Stem cell therapy for AD focuses on restoring lost neurons and improving the brain’s ability to function and heal. Studies using human neural stem cells in animal models of Alzheimer’s have shown that these cells can improve learning and memory, possibly by enhancing synaptic plasticity and increasing the production of proteins involved in cognitive function.
However, challenges remain, including understanding how these stem cells exert their effects and controlling the formation of unwanted cell types. Researchers are currently exploring the use of nerve growth factor (NGF) in combination with stem cells to protect existing neurons and encourage the growth of new ones.
NGF gene therapy has shown promise in early trials and may help amplify the positive effects of stem cell treatment.
Stem Cell Therapy for ALS (Amyotrophic Lateral Sclerosis)
Amyotrophic lateral sclerosis, or ALS, is another devastating condition in which motor neurons in the brain and spinal cord gradually die, leading to muscle weakness, paralysis, and ultimately death, typically within a few years of diagnosis. Most cases are sporadic and occur without a clear genetic cause, though some cases are linked to inherited gene mutations. Because multiple mechanisms may contribute to the disease, including protein misfolding, oxidative stress, and inflammation, it has been extremely difficult to find effective treatments.
Stem cell research in ALS is still in the early stages, but it holds potential. The goal is not necessarily to replace the lost motor neurons – which is extremely difficult – but rather to create a supportive environment that preserves the neurons that remain and slows disease progression.
Some clinical trials have tested the use of MSCs and neural stem cells (NSCs) injected directly into the spinal cord. Results from these early studies suggest that the treatments are safe and may help stabilize function in some patients. In animal models, stem cell transplants have been shown to reduce inflammation, promote motor neuron survival, and improve muscle strength.
As with other neurodegenerative diseases, the success of stem cell therapy in ALS will likely depend on a deeper understanding of disease mechanisms and finding the best ways to target and deliver treatment.
The Future of Stem Cell Therapy for Neurodegenerative Diseases
While stem cell therapy is not yet a viable cure for neurodegenerative diseases, Sivandzade et al. believe it represents one of the most promising paths forward. The ability to regenerate or repair damaged tissue offers hope where traditional therapies have fallen short. As research continues to advance, more clinical trials are likely to explore the safety and effectiveness of these treatments, along with better methods for personalizing therapies and improving the delivery of stem cells to targeted areas within the nervous system.
Source: Sivandzade F, Cucullo L. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. Int J Mol Sci. 2021 Feb 22;22(4):2153. doi: 10.3390/ijms22042153. PMID: 33671500; PMCID: PMC7926761.
Spinal cord injury (SCI) is one of the most serious outcomes of spinal trauma. It typically leads to either temporary or permanent loss of sensory, motor, and autonomic nerve functions below the affected area and can significantly impact a person’s quality of life. Worldwide, approximately 10.5 out of every 100,000 people experience SCI. While modern treatments enable 94% of individuals with acute traumatic SCI to survive, long-term survival is often compromised by complications arising after the injury.
In this review, Xia et al. explores the pathophysiological changes that occur following SCI and examines the mechanisms through which MSCs contribute to treatment. The authors also summarize the potential clinical applications of MSCs while addressing the challenges associated with their use and discussing future prospects.
Current Treatment Approaches For SCI
Current therapies for SCI focus on managing the immediate effects of the injury. Standard treatments include stabilizing the spine, surgically decompressing the spinal canal, and initiating rehabilitation programs. These approaches aim to reduce further damage and create conditions that support natural healing processes. However, they do not actively promote the regeneration of damaged nerve cells. The primary goal is to restore neurological function as quickly as possible after addressing the spinal cord compression. Unfortunately, no existing treatment strategies can fully repair damaged nerve cells, leaving an unmet need for innovative therapies.
Primary Spinal Cord Injury
Primary SCI results from direct trauma, such as fractures or dislocations of the vertebrae, which can compress, tear, or even sever the spinal cord. Spinal cord compression is the most common form of primary injury and is often accompanied by damage to blood vessels and the blood-spinal cord barrier (BSCB). The BSCB is a critical structure that maintains the stability and health of the spinal cord by keeping harmful substances out. When the BSCB is compromised, inflammatory molecules and toxic substances infiltrate the injured area, worsening the damage.
Secondary Spinal Cord Injury
Secondary SCI involves a series of biological processes that start within minutes of the initial injury. These changes occur in three overlapping phases: acute (within 48 hours), subacute (48 hours to two weeks), and chronic (lasting up to six months). Secondary injuries can exacerbate the damage caused by the primary injury and often lead to permanent complications.
One of the first effects of secondary SCI is the disruption of the blood supply to the spinal cord, which causes further cell death. As spinal cord cells are destroyed, they release molecules that trigger inflammation. This inflammatory response attracts immune cells to the injury site, which, in turn, release substances that cause additional damage. Neutrophils, a type of immune cell, arrive within an hour of injury and persist for several days, contributing to the worsening of the injury by releasing harmful substances like reactive oxygen species.
The Role of Mesenchymal Stem Cells in SCI
In recent years, mesenchymal stem cells (MSCs) have emerged as a promising option for treating SCI. MSCs are a type of stem cell capable of self-renewal and differentiation into various cell types, making them suitable for tissue repair and regeneration. These cells can be derived from multiple sources, including bone marrow, fat tissue, umbilical cords, and amniotic fluid. MSCs are relatively easy to isolate and store, and their use does not raise significant ethical concerns.
Types of MSCs
The three main types of MSCs used in clinical practice are bone marrow-derived MSCs (BMSCs), adipose-derived MSCs (AD-MSCs), and human umbilical cord-derived MSCs (HUC-MSCs). Each type has unique advantages:
BMSCs: These cells can differentiate into various tissue types, such as bone, cartilage, and nerve cells. They are effective at reducing inflammation and releasing factors that support nerve regeneration.
AD-MSCs: Sourced from fat tissue, these cells are easier to obtain in large quantities without causing significant harm. They promote angiogenesis (the formation of new blood vessels) and wound healing by releasing growth factors and other molecules.
HUC-MSCs: These cells have the highest capacity for proliferation and differentiation. They are smaller in size, allowing them to pass through the BSCB more easily, and they do not pose a risk of fat or vascular embolism.
How MSCs Assist in Treatment of SCI
According to the authors, MSCs offer multiple benefits for SCI treatment, including:
Immunomodulation: MSCs regulate the immune response at the injury site by interacting with immune cells and releasing anti-inflammatory molecules. This helps reduce inflammation, which is a key factor in secondary injury.
Neuroprotection and Regeneration: MSCs release neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), which promote the survival and regeneration of nerve cells. They also inhibit glial scarring, a process that can block nerve regeneration.
Angiogenesis: MSCs secrete vascular endothelial growth factor (VEGF) and other molecules that encourage the formation of new blood vessels. This improves blood flow to the injured area and helps restore the damaged BSCB.
Exosome Production: MSCs release exosomes, small vesicles that carry proteins and genetic material to the injury site. These exosomes play a crucial role in reducing inflammation, promoting cell repair, and improving overall tissue recovery.
Future Directions
MSC therapy holds significant promise for improving outcomes in SCI patients. Preclinical studies have demonstrated the ability of MSCs to restore motor function in animal models. In clinical settings, MSCs have shown potential in improving sensory and motor function and aiding bladder control in patients with SCI. However, further research is needed to refine the therapy and address existing challenges.
Mesenchymal Stem Cells: A Promising Path for Spinal Cord Injury Treatment
SCI is a complex condition with devastating consequences for those affected. Current treatments aim to stabilize the injury and create conditions for natural healing but fall short of promoting nerve regeneration. MSCs offer a new avenue for SCI treatment by reducing inflammation, supporting nerve cell regeneration, and improving blood flow to the injured area. While challenges remain, the authors conclude that the advancements in MSC research suggest a bright future for their use in SCI therapy. With continued investigation, MSCs has the potential to become a cornerstone of regenerative medicine for SCI patients.
Source: Xia Y, Zhu J, Yang R, Wang H, Li Y, Fu C. Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges. Front Immunol. 2023 Feb 24;14:1141601. doi: 10.3389/fimmu.2023.1141601. PMID: 36911700; PMCID: PMC9999104.
Parkinson’s disease (PD) is a neurodegenerative disorder affecting millions worldwide, causing debilitating symptoms such as tremors, rigidity, and difficulty walking. Existing treatments primarily manage symptoms without addressing the underlying causes, highlighting the need for more effective therapeutic approaches. Mesenchymal stem cell (MSC) therapy has emerged as a promising option, demonstrating potential neuroprotective, anti-inflammatory, and regenerative benefits.
As part of this review, Tambe et al. examine preclinical and clinical evidence on MSCs and their derivatives, including secretomes and exosomes, in PD management. The authors also analyze challenges and limitations of each approach, including delivery methods, timing of administration, and long-term safety considerations.
The Growing Challenge of Parkinson’s Disease
PD, along with other age-related diseases like Alzheimer’s and stroke, is becoming more prevalent due to increased life expectancy. The disease affects 2–3% of individuals over 65, and by 2040, the number of people living with PD is expected to double. In 2019, PD caused the loss of 5.8 million disability-adjusted life years (DALYs), a significant rise from 2000.
PD symptoms include postural instability, muscle hypertonia, bradykinesia, resting tremor, and cognitive and language abnormalities, all of which negatively impact the quality of life. PD is diagnosed based on motor symptoms, but non-motor symptoms also contribute to disability.
Parkinson’s disease primarily results from the accumulation of α-synuclein and a depletion of dopamine due to neuronal loss in the substantia nigra. It also involves disruptions in multiple pathways, including α-synuclein proteostasis, mitochondrial dysfunction, oxidative stress, and neuroinflammation.
Current Treatments for Parkinson’s Disease
While there is no cure for PD, current symptomatic treatments include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, deep brain stimulation, and lesion surgery. However, these therapies are limited and do not address the underlying causes of the disease.
Newer interventions like stem cell therapy, neurotrophic factors, and gene therapy aim to address the root causes and potentially slow or stop disease progression.
Cell-based Therapies for Parkinson’s Disease Cell-based therapies are gaining attention as potential treatments for PD due to their ability to slow disease progression and replace lost dopamine production. Several cell sources are being researched for their therapeutic potential, each with specific advantages and disadvantages.
Mesenchymal stem cells (MSCs) are particularly promising due to their unique properties, including self-renewal and multi-potent differentiation potential. MSCs can differentiate into various cell types, including neuronal-like cells, and exhibit therapeutic effects through both cellular differentiation and the paracrine action of secreted growth factors.
Properties of Mesenchymal Stem Cells (MSCs)
MSCs are plastic-adherent cells capable of self-renewal and differentiation into various lineages, including neurons, adipocytes, osteoblasts, chondrocytes, and endothelial cells. This versatility makes MSCs an attractive option for treating PD.
MSCs also have the potential to exert therapeutic effects through the secretion of factors that promote cell survival, tissue regeneration, and anti-inflammatory actions. In addition to their ability to differentiate into mesodermal lineages, MSCs can produce secretomes and exosomes, which are small vesicles containing proteins, RNA, and other molecules that have demonstrated the ability to influence surrounding cells.
Therapeutic Success of MSCs in PD Management
Preclinical studies on MSCs and their derivatives, including secretomes and exosomes, have shown promising results in PD animal models. MSCs may promote the survival of dopamine-producing neurons and protect against neurodegeneration. Their secretomes, which contain bioactive molecules, can modulate inflammation and stimulate tissue repair. Exosomes, which are extracellular vesicles derived from MSCs, have been shown to improve neuronal function and survival in PD models. These findings suggest that MSC-based therapies could offer a novel approach to managing PD, potentially slowing disease progression and improving motor and cognitive symptoms.
Alternative Delivery Methods for MSC Therapy
One of the significant challenges in MSC therapy for PD is the delivery of these cells to the brain, particularly through the blood-brain barrier (BBB), which restricts the entry of most drugs.
Traditional delivery methods, such as intravenous, intracerebral, and intramuscular routes, have limitations in terms of efficacy and invasiveness.
Recent research has explored intranasal delivery of MSCs and their derivatives as a promising alternative. Intranasal administration could allow MSCs and their secretomes to bypass the BBB, delivering therapeutic agents directly to the central nervous system with minimal invasiveness.
The Future of MSC Therapy for Parkinson’s Disease
MSC-released exosomes and extracellular vesicles are gaining attention as potential treatments for PD due to their improved ability to cross the BBB and target specific cells. These vesicles can transport proteins, growth factors, microRNAs, and other bioactive molecules to recipient cells, potentially enhancing the therapeutic effects of MSCs.
Intranasal delivery of MSCs and their exosomes is an exciting area of research, offering a less invasive method for delivering therapy directly to the brain. This approach could lead to improved outcomes in PD management, especially if combined with other therapies that address the underlying causes of the disease.
Tambe et al. conclude that MSC therapy and its derivatives, such as secretomes and exosomes, hold significant promise for the treatment of Parkinson’s disease. However, challenges such as MSC heterogeneity, delivery methods, and long-term safety must be addressed before MSC-based therapies can become a mainstream treatment for PD.
Source: Tambe P, Undale V, Sanap A, Bhonde R, Mante N. The prospective role of mesenchymal stem cells in Parkinson’s disease. Parkinsonism Relat Disord. 2024 Oct;127:107087. doi: 10.1016/j.parkreldis.2024.107087. Epub 2024 Aug 10. PMID: 39142905.
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Subscribe To Our Newsletter
Join our mailing list to receive the latest news and updates from our team.
You have Successfully Subscribed!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
St. Petersburg, Florida
